Latest News

We are building a very different antibiotics company that focuses on bringing innovation to antibiotic development. Our new mechanism antibiotics are designed to become the new standards of care for the benefit of patients and create value for payors and healthcare providers.

Glyn Edwards
Chief Executive Officer

For Investors

Visit our dedicated section for investors that contains the latest available financial and regulatory information

Latest Event

Watch our webcast presentation at the Rodman & Renshaw Global Investment Conference

Our Discuva Platform

Our technology platform is at the heart of our research to develop new mechanism antibiotics